Codexis (NASDAQ:CDXS – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Profitability
This table compares Codexis and Icon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Codexis | -39.55% | -74.36% | -23.58% |
| Icon | 3.99% | 8.02% | 4.56% |
Analyst Ratings
This is a summary of current recommendations for Codexis and Icon, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Codexis | 1 | 0 | 1 | 0 | 2.00 |
| Icon | 2 | 7 | 7 | 1 | 2.41 |
Risk and Volatility
Codexis has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, Icon has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Institutional and Insider Ownership
78.5% of Codexis shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Codexis and Icon”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Codexis | $70.39 million | 2.43 | -$43.97 million | ($0.34) | -4.59 |
| Icon | $8.25 billion | 1.51 | $229.34 million | $4.26 | 38.30 |
Icon has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Summary
Icon beats Codexis on 12 of the 15 factors compared between the two stocks.
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
About Icon
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
